{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:23:06Z","timestamp":1788211386707,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1RO1 NS42240"],"award-info":[{"award-number":["1RO1 NS42240"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 MH049351"],"award-info":[{"award-number":["P01 MH049351"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 MH061940"],"award-info":[{"award-number":["R01 MH061940"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K05 MH076273"],"award-info":[{"award-number":["K05 MH076273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>Despite the significant burden of disease associated with infection by group A streptococcus (GAS), little is known about the human immune response to GAS antigens after natural infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We evaluated 195 serum samples obtained prospectively over a consecutive 24-month period from 41 pediatric subjects who experienced a new pharyngeal GAS acquisition. An enzyme-linked immunoassay was used to determine the kinetics and antigen specificity of antibodies against 13 shared GAS antigens and 18 type-specific M peptides. The majority of the antigens tested are currently being considered as vaccine candidates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Twelve M types of GAS were recovered from 41 subjects who experienced 51 new GAS acquisitions that elicited antibody responses against at least 1 of the 31 antigens tested (immunologically significant new GAS acquisitions). The immune responses to the 13 shared antigens were highly variable. Increases in antibody levels were detected against a mean of 3.5 shared antigens (range, 1\u20138). Antibody responses to the homologous M peptide were observed in 32 (63%) of the 51 episodes. Seven subjects acquired more than 1 M type of GAS. There were no new immunologically significant acquisitions of an M type against which the subject had preexisting antibodies to the homologous M peptide. Of the subjects with new GAS acquisition, 65% were asymptomatic, yet immune responses were detected against 1 or more GAS antigens. Immune responses to streptolysin O and\/or deoxyribonuclease B were observed after 67% of the new GAS acquisitions. Persistently positive (&amp;gt;12 weeks) throat culture results were returned for 20% of the 41 subjects despite immune responses to homologous M peptides and\/or shared antigens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>The availability of throat culture results, GAS isolates, and serial serum samples collected prospectively over a 2-year period of observation provided a unique opportunity for us to assess the serologic status of pediatric subjects before and after new pharyngeal acquisitions of GAS. With the exception of antibody responses to the homologous M peptides, no clear pattern of immune responses against the remaining GAS antigens was seen. There were no new immunologically significant acquisitions ofemm types of GAS against which the subjects had preexisting elevated levels of antibodies against the homologous M peptide. The observation that 65% of new GAS acquisitions caused no symptoms yet were immunologically significant suggests that the majority of infections are not detected, which would result in missed opportunities for primary prevention of rheumatic fever and rheumatic heart disease with appropriate antimicrobial therapy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jpids\/piw070","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T14:19:40Z","timestamp":1476195580000},"page":"187-196","source":"Crossref","is-referenced-by-count":63,"title":["Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci"],"prefix":"10.1093","volume":"6","author":[{"given":"Nicholas D.","family":"Hysmith","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center and Department of Veterans Affairs Research Service,Memphis, Tennessee;"},{"name":"St. Jude Children\u2019s Research Hospital,Memphis, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Patrick","family":"Cleary","sequence":"first","affiliation":[{"name":"Microbiology,University of Minnesota,Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight R.","family":"Johnson","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Penfound","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center and Department of Veterans Affairs Research Service,Memphis, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Dale","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center and Department of Veterans Affairs Research Service,Memphis, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2020060117000477100_CIT0001","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2020060117000477100_CIT0002","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.89.3.307","article-title":"Current knowledge of the type specific M antigens of group A streptococci","volume":"89","author":"Lancefield","year":"1962","journal-title":"J Immunol"},{"key":"2020060117000477100_CIT0003","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1172\/JCI103504","article-title":"Type-specific streptococcal antibody","volume":"36","author":"Denny","year":"1957","journal-title":"J Clin Invest"},{"key":"2020060117000477100_CIT0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/intimm\/dxn004","article-title":"Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever","volume":"20","author":"Martins","year":"2008","journal-title":"Int Immunol"},{"key":"2020060117000477100_CIT0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1086\/377700","article-title":"Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development","volume":"188","author":"Shet","year":"2003","journal-title":"J Infect Dis"},{"key":"2020060117000477100_CIT0006","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1016\/j.vaccine.2010.05.018","article-title":"Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes","volume":"28","author":"Penfound","year":"2010","journal-title":"Vaccine"},{"key":"2020060117000477100_CIT0007","first-page":"347","article-title":"Studies on immunity to streptococcal infections in man","volume":"86","author":"Wannamaker","year":"1953","journal-title":"AMA Am J Dis Child"},{"key":"2020060117000477100_CIT0008","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vaccine.2012.09.045","article-title":"Group A streptococcal vaccines: paving a path for accelerated development","volume":"31","author":"Dale","year":"2013","journal-title":"Vaccine"},{"key":"2020060117000477100_CIT0009","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1086\/444505","article-title":"Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles\u2014report of a National Institute of Allergy and Infectious Diseases workshop","volume":"41","author":"Bisno","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020060117000477100_CIT0010","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1542\/peds.2007-2657","article-title":"Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study","volume":"121","author":"Kurlan","year":"2008","journal-title":"Pediatrics"},{"key":"2020060117000477100_CIT0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaac.2010.10.011","article-title":"Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study","volume":"50","author":"Leckman","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2020060117000477100_CIT0012","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1086\/650167","article-title":"The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications","volume":"50","author":"Johnson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020060117000477100_CIT0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/599344","article-title":"Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates","volume":"49","author":"Shulman","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020060117000477100_CIT0014","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"key":"2020060117000477100_CIT0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/CVI.00795-14","article-title":"Protective immunogenicity of group A streptococcal M-related proteins","volume":"22","author":"Dale","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"2020060117000477100_CIT0016","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","article-title":"Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils","volume":"73","author":"Park","year":"2005","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0017","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1096\/fj.09-145631","article-title":"Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features","volume":"24","author":"Zingaretti","year":"2010","journal-title":"FASEB J"},{"key":"2020060117000477100_CIT0018","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1128\/IAI.71.9.5097-5103.2003","article-title":"Serum opacity factor (SOF) ofStreptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci","volume":"71","author":"Courtney","year":"2003","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0019","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1128\/IAI.64.7.2415-2419.1996","article-title":"Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells","volume":"64","author":"Courtney","year":"1996","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0020","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1128\/IAI.00064-14","article-title":"SpyAD, a moonlighting protein of group AStreptococcus contributing to bacterial division and host cell adhesion","volume":"82","author":"Gallotta","year":"2014","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0021","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1084\/jem.161.3.547","article-title":"Human immune response to group A streptococcal carbohydrate (A-CHO). I. Quantitative and qualitative analysis of the A-CHO-specific B cell population responding in vitro to polyclonal and specific activation","volume":"161","author":"Emmrich","year":"1985","journal-title":"J Exp Med"},{"key":"2020060117000477100_CIT0022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0022-1759(79)90340-5","article-title":"ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes","volume":"28","author":"Gray","year":"1979","journal-title":"J Immunol Methods"},{"key":"2020060117000477100_CIT0023","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1128\/IAI.72.5.2507-2512.2004","article-title":"Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections","volume":"72","author":"Hall","year":"2004","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0024","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.aje.a113495","article-title":"Type-specific immunity and pharyngeal acquisition of group AStreptococcus","volume":"116","author":"Guirguis","year":"1982","journal-title":"Am J Epidemiol"},{"key":"2020060117000477100_CIT0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00006454-198507000-00008","article-title":"Acquisition of group A streptococcal M protein antibodies","volume":"4","author":"Quinn","year":"1985","journal-title":"Pediatr Infect Dis"},{"key":"2020060117000477100_CIT0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198702193160801","article-title":"Resurgence of acute rheumatic fever in the intermountain region of the United States","volume":"316","author":"Veasy","year":"1987","journal-title":"N Eng J Med"},{"key":"2020060117000477100_CIT0027","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jama.1969.03160310050009","article-title":"A community-wide study of acute rheumatic fever in adults. Epidemiologic and preventive factors","volume":"210","author":"Gordis","year":"1969","journal-title":"JAMA"},{"key":"2020060117000477100_CIT0028","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.109.191959","article-title":"Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease","volume":"119","author":"Gerber","year":"2009","journal-title":"Circulation"},{"key":"2020060117000477100_CIT0029","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/01.CIR.21.4.598","article-title":"Antibody titers in acute rheumatic fever","volume":"21","author":"Wannamaker","year":"1960","journal-title":"Circulation"},{"key":"2020060117000477100_CIT0030","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1016\/j.vaccine.2010.04.094","article-title":"Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads","volume":"28","author":"Madore","year":"2010","journal-title":"Vaccine"},{"key":"2020060117000477100_CIT0031","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","volume":"70","author":"Hu","year":"2002","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0032","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"key":"2020060117000477100_CIT0033","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0264-410X(97)00178-3","article-title":"Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci","volume":"15","author":"Brandt","year":"1997","journal-title":"Vaccine"},{"key":"2020060117000477100_CIT0034","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1128\/IAI.65.6.2080-2087.1997","article-title":"Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus","volume":"65","author":"Ji","year":"1997","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0035","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1128\/IAI.60.12.5219-5223.1992","article-title":"Streptococcal C5a peptidase is a highly specific endopeptidase","volume":"60","author":"Cleary","year":"1992","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0036","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1086\/603541","article-title":"Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinicalStreptococcus pyogenes infection","volume":"200","author":"Turner","year":"2009","journal-title":"J Infect Dis"},{"key":"2020060117000477100_CIT0037","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1128\/IAI.00038-07","article-title":"Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci","volume":"75","author":"Liu","year":"2007","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0038","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00284-001-0037-1","article-title":"Mapping the fibrinogen-binding domain of serum opacity factor of group A streptococci","volume":"44","author":"Courtney","year":"2002","journal-title":"Curr Microbiol"},{"key":"2020060117000477100_CIT0039","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/IAI.69.2.924-930.2001","article-title":"Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses againstStreptococcus pyogenes challenge in mice","volume":"69","author":"Kawabata","year":"2001","journal-title":"Infect Immun"},{"key":"2020060117000477100_CIT0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical Lancefield antigen of group AStreptococcus is a virulence determinant with implications for vaccine design","volume":"15","author":"Van Sorge","year":"2014","journal-title":"Cell Host Microbe"},{"key":"2020060117000477100_CIT0041","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/498618","article-title":"Group AStreptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection","volume":"193","author":"Sabharwal","year":"2006","journal-title":"J Infect Dis"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/6\/2\/187\/33334247\/piw070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/6\/2\/187\/33334247\/piw070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T11:45:52Z","timestamp":1692531952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/6\/2\/187\/2997414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piw070","relation":{},"ISSN":["2048-7193","2048-7207"],"issn-type":[{"value":"2048-7193","type":"print"},{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,2,15]]}}}